Rituximab: emerging treatment strategies of immune-mediated glomerular disease.

about

Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis.Treatment of primary membranous nephropathy: where are we now?

P2860

Q38408710-94617545-D74E-40B5-A3B1-7FA1F04A86D2 Q47850601-742EDAB9-0898-452A-8DCD-A03A1745B508

P2860

Rituximab: emerging treatment strategies of immune-mediated glomerular disease.

Item

http://www.wikidata.org/entity/Q38033648

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Rituximab: emerging treatment strategies of immune-mediated glomerular disease.

@en

type

Item

label

Rituximab: emerging treatment strategies of immune-mediated glomerular disease.

@en

prefLabel

Rituximab: emerging treatment strategies of immune-mediated glomerular disease.

@en

P1476

Rituximab: emerging treatment strategies of immune-mediated glomerular disease.

@en

P2093

Andrea G Kattah

http://www.w3.org/2001/XMLSchema#string

Fernando C Fervenza

http://www.w3.org/2001/XMLSchema#string

P2860

M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy

Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.

Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease.

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.

Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.

Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.

Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies.

P304

413-421

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ECI.12.26

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22882216

http://www.w3.org/2001/XMLSchema#string

Rituximab: emerging treatment strategies of immune-mediated glomerular disease.

about

P2860

P2860

Rituximab: emerging treatment strategies of immune-mediated glomerular disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698